Latest Advances in Lung Cancer Research

Not long ago, lung cancer had almost no organized patient advocacy and nowhere near the visibility that breast cancer or pediatric cancer communities had built. A new article in the Journal of Thoracic Oncology, co-written by four advocates and researchers — including LCFA’s own Jill Feldman — traces how that changed over the past two decades, and what’s still unfinished.

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

Discover why 9 in 10 lung cancer patients miss out on clinical trial discussions and how asking one key question early can unlock life-saving options.

New study shows counting smoking years, not cigarette amount, could catch more lung cancers and make screening fairer for veterans.

Lung cancer cells can revert to an earlier developmental form, driving aggression and treatment resistance, offering new clues for personalized therapy.

Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.

New drug ivonescimab cut death risk 34% in lung cancer trial, outperforming standard immunotherapy plus chemo combination.

Selpercatinib cut lung cancer recurrence risk by 83% in patients with rare RET-positive early-stage non-small cell lung cancer.

A new lung cancer drug is making headlines. At the 2026 ASCO meeting, researchers shared exciting results for a drug called ivonescimab. In a large study, it lowered the risk of death by 34% for people with a hard-to-treat type of lung cancer.